On April 9, 2025 TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (OTC: TCBPY) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, reported receipt of a patent, granted from the European Patent Office (EPO), for targeting microbial, oncological, and viral indications using modified gamma delta T cells (Press release, TC Biopharm, APR 9, 2025, View Source [SID1234651859]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company intends to proceed with the patent process in specific European countries, in alignment with the existing commercial strategy.

"The expanding patent portfolio secures our future development of high-value assets," said Bryan Kobel, CEO of TC BioPharm. "The potential for off-target recognition of healthy tissues limits the application of modified cell therapies. By refining the targeting of these modified cells, we can apply high-impact therapies to a broad spectrum of indications while mitigating the toxicity risks associated with modified cell therapies."